Disease · HP_0000737
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All AVP-786 vs All Placebo: deaths from any cause | 0 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| All AVP-786 vs All Placebo: serious adverse events | 3 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| Amantadine vs Placebo: serious adverse events | 3 of 82 | 2 of 86 | 168 | NCT00779324 | Trial comparisons |
| STX209 vs Placebo: serious adverse events | 1 of 63 | 0 of 63 | 126 | NCT00788073 | Trial comparisons |
| Brexpiprazole vs Placebo: deaths from any cause | 0 of 58 | 0 of 57 | 115 | NCT04174365 | Trial comparisons |
| Brexpiprazole vs Placebo: serious adverse events | 0 of 58 | 0 of 57 | 115 | NCT04174365 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS) | 4 of 49 | 2 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: deaths from any cause | 0 of 49 | 0 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values | 6 of 49 | 4 of 46 | 95 | NCT04258839 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: serious adverse events | 2 of 49 | 1 of 46 | 95 | NCT04258839 | Trial comparisons |
| Carbamazepine vs Placebo: deaths from any cause | 0 of 35 | 0 of 35 | 70 | NCT00621751 | Trial comparisons |
| Carbamazepine vs Placebo: serious adverse events | 6 of 35 | 1 of 35 | 70 | NCT00621751 | Trial comparisons |
| Carbamazepine vs Placebo: Proportion of Participants With Minimal Clinically Important Difference -- Observer Rating | 20 of 35 | 26 of 34 | 69 | NCT00621751 | Trial comparisons |
| Carbamazepine vs Placebo: Proportion of Participants With Minimal Clinically Important Difference (MCID) -- Participant | 21 of 32 | 16 of 30 | 62 | NCT00621751 | Trial comparisons |
| Add-on Citalopram Following Optimized Methylphenidate vs Add-on Placebo Following Optimized Methylphenidate: deaths from any cause | 0 of 23 | 0 of 26 | 49 | NCT00794040 | Trial comparisons |
| Add-on Citalopram Following Optimized Methylphenidate vs Add-on Placebo Following Optimized Methylphenidate: serious adverse events | 0 of 23 | 0 of 26 | 49 | NCT00794040 | Trial comparisons |
| Dextromethorphan/Quinidine 20mg/10mg (DM/Q 20mg/10mg) vs Placebo: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT03854019 | Trial comparisons |
| Dextromethorphan/Quinidine 20mg/10mg (DM/Q 20mg/10mg) vs Placebo: serious adverse events | 0 of 20 | 1 of 20 | 40 | NCT03854019 | Trial comparisons |
Dextromethorphan/Quinidine 20mg/10mg (DM/Q 20mg/10mg) vs Placebo: Number of Participants With Behavioral Suicidal Events, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Behavior. | 0 of 18 | 0 of 18 | 36 | NCT03854019 | Trial comparisons |
Dextromethorphan/Quinidine 20mg/10mg (DM/Q 20mg/10mg) vs Placebo: Number of Participants With Behavioral Suicidal Events, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) - Suicidal Ideation | 0 of 18 | 0 of 18 | 36 | NCT03854019 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000737/comparisons